DreamCIS Past Earnings Performance

Past criteria checks 3/6

DreamCIS's earnings have been declining at an average annual rate of -0.4%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 23.6% per year. DreamCIS's return on equity is 6.8%, and it has net margins of 8.2%.

Key information

-0.4%

Earnings growth rate

-7.3%

EPS growth rate

Life Sciences Industry Growth53.7%
Revenue growth rate23.6%
Return on equity6.8%
Net Margin8.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

A Look At The Fair Value Of DreamCIS, Inc. (KOSDAQ:223250)

Dec 17
A Look At The Fair Value Of DreamCIS, Inc. (KOSDAQ:223250)

DreamCIS, Inc.'s (KOSDAQ:223250) Shares Climb 29% But Its Business Is Yet to Catch Up

Oct 21
DreamCIS, Inc.'s (KOSDAQ:223250) Shares Climb 29% But Its Business Is Yet to Catch Up

DreamCIS, Inc.'s (KOSDAQ:223250) 29% Price Boost Is Out Of Tune With Earnings

Jul 11
DreamCIS, Inc.'s (KOSDAQ:223250) 29% Price Boost Is Out Of Tune With Earnings

DreamCIS, Inc.'s (KOSDAQ:223250) Share Price Not Quite Adding Up

Apr 26
DreamCIS, Inc.'s (KOSDAQ:223250) Share Price Not Quite Adding Up

We Think You Should Be Aware Of Some Concerning Factors In DreamCIS' (KOSDAQ:223250) Earnings

Mar 20
We Think You Should Be Aware Of Some Concerning Factors In DreamCIS' (KOSDAQ:223250) Earnings

Estimating The Intrinsic Value Of DreamCIS, Inc. (KOSDAQ:223250)

Mar 19
Estimating The Intrinsic Value Of DreamCIS, Inc. (KOSDAQ:223250)

Revenue & Expenses Breakdown

How DreamCIS makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A223250 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2456,8834,67410,994733
30 Jun 2453,1213,82010,585733
31 Mar 2449,7713,7209,917733
31 Dec 2347,8443,7399,223733
30 Sep 2346,4912,2859,366440
30 Jun 2342,9574,1088,495440
31 Mar 2342,6574,6467,667440
31 Dec 2238,8744,4056,461440
30 Sep 2235,7785,5286,048277
30 Jun 2231,4764,2295,365277
31 Mar 2227,1332,8884,584277
31 Dec 2126,1533,2294,470277
30 Sep 2123,2342,6124,306316
30 Jun 2122,6522,8754,279316
31 Mar 2123,4984,5424,322316
31 Dec 2023,4894,8544,297316
30 Sep 2023,0514,2484,267141
31 Dec 1922,1094,1513,762141

Quality Earnings: A223250 has a large one-off gain of ₩1.8B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A223250's current net profit margins (8.2%) are higher than last year (4.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A223250's earnings have declined by 0.4% per year over the past 5 years.

Accelerating Growth: A223250's earnings growth over the past year (104.5%) exceeds its 5-year average (-0.4% per year).

Earnings vs Industry: A223250 earnings growth over the past year (104.5%) exceeded the Life Sciences industry 39.6%.


Return on Equity

High ROE: A223250's Return on Equity (6.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 07:21
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DreamCIS, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyun Dong LeeNH Investment & Securities Co., Ltd.